A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes in a safety-net institution by Weiner, Michael et al.
A randomized naturalistic study of an electronic hypoglycemia risk calculator
in outpatient primary care
Michael Weiner,1,2,3 Jonathan Cummins,1 Annaswamy Raji,4 Susan Ofner,5 Kristy Iglay,4
Evgenia Teal,1 Xiaochun Li,5 Samuel S. Engel,4 Kristina Knapp,1 Swapnil Rajpathak,4
Jarod Baker,1 Arnaub K. Chatterjee,4 and Larry Radican4
1Regenstrief Institute, Inc., Indianapolis, Indiana
2Indiana University Center for Health Services and Outcomes Research, Indianapolis, Indiana
3Center for Health Information and Communication, U.S. Department of Veterans Affairs, 
Veterans Health Administration,
Health Services Research and Development Service CIN 13-416, Richard L. Roudebush VA 
Medical Center, Indianapolis, Indiana
4Merck & Co., Inc., Kenilworth, New Jersey
5Indiana University Department of Biostatistics, Indianapolis, Indiana
Correspondence:
Michael Weiner, M.D., M.P.H.
Regenstrief Institute, Inc.





Word count for all text: 8384
Key words: Hypoglycemia; Diabetes Mellitus; Decision Support Systems, Clinical; Electronic 
Health Records
Source of funding: Merck & Co., Inc., Kenilworth, New Jersey

























































This is the author's manuscript of the article published in final edited form as:
Weiner, M., Cummins, J., Raji, A., Ofner, S., Iglay, K., Teal, E., Li, X., Engel, S. S., Knapp, K., Rajpathak, S., Baker, J., Chatterjee, A. K., & Radican, L. 
(2020). A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes 




Objective. Hypoglycemia (HG) occurs in up to 60% of patients with diabetes mellitus (DM) each 
year. Our objective was to assess a HG alert tool in an electronic health record system, and 
determine the tool's effect on clinical practice and outcomes.
Methods. The tool used a logistic-regression model to provide patient-specific information about 
HG risk. We randomized academic outpatient primary-care providers (PCPs) to see or not see 
the alerts. Adult patients were assigned to study group according to the first PCP seen during 
four months. We assessed five months' prescriptions, diagnostic testing, and HG. Categorical 
variables were compared by multinomial model, binary variables by logistic model, and 
continuous variables by linear model.
Results. A total of 3350 patients visited 123 intervention PCPs; 3395 patients visited 220 control 
PCPs. Intervention PCPs were shown 18,645 alerts. Patients' mean age was 55 years, with 61% 
female, 49% black, and 49% with Medicaid. Mean baseline A1c (8.7%) and body mass index 
(35.2 kg/m2) were similar between groups. During follow-up, the number of A1c and glucose 
tests, and number of new, refilled, changed, or discontinued insulin prescriptions, were highest 
for patients with highest risk. Per 100 patients, the intervention group had significantly fewer 
sulfonylurea refills (6 vs. 8; p<0.05) and outpatient encounters (470 vs. 502; p<0.05). Frequency 
of A1c testing and HG events was unchanged.
Conclusions. Informing PCPs about risk of HG led to fewer sulfonylurea refills and visits. 
Longer-term studies are needed to assess the potential for long-term benefits of the alert.
































































Diabetes mellitus (DM) is one of the most common non-communicable diseases 
worldwide and is a major cause of morbidity and mortality. In 2010, DM was the seventh leading 
cause of death in the United States. In 2015, DM was present in more than 30 million Americans 
(9.4%) and about 25% of those 65 or more years of age (1). Hypoglycemia (HG) is recognized as 
the major limiting factor in optimal glycemic management for patients with both type 1 and type 
2 diabetes (2-5). It has substantial negative effects on cardiovascular safety and quality of life (6-
11). It also increases economic costs via healthcare utilization and lost productivity (12).
HG threatens safety and glycemic control (10, 13-16). The risk of HG increased 
substantially in landmark studies designed to show that intensive treatment to maintain near 
euglycemia (normoglycemia) significantly reduced long-term risks of vascular complications 
(16-18). In the Diabetes Control and Complications Trial (DCCT), patients with type 1 DM 
randomized to intensive therapy had about a three-fold higher risk of severe HG compared with 
their counterparts receiving conventional treatment (16). In the 4-T study of type 2 DM, the 
mean number of HG events per patient in individuals treated with insulin ranged from 2.3 to 12.0 
per year, although less than 1 in 4 patients achieved A1C less than 6.5% (19). HG also occurs in 
approximately 20% to 60% of patients with type 2 DM who received oral medications according 
to some studies (10, 13-15, 20). A systematic review and meta-analysis of more than 500,000 
patients showed that mild or moderate HG occurred in 45% of patients with type 2 diabetes on 
oral therapies or insulin, while severe HG occurred in 6% (20). In a recent survey of 1,984 adults 
with type 2 DM who received oral antihyperglycemic medications, 63% reported having at least 
one HG episode in the previous six months. Of these episodes, 46% were mild, 37% moderate, 
13% severe, and 4% very severe (13). In a population more than 80 years of age with type 2 DM, 































































25% of hospital admissions associated with DM were due to severe HG (21). Newer drugs have 
led to somewhat lower risk. For example, a cohort study of more than 50,000 patients with type 2 
DM showed a lower odds of severe HG in patients receiving a dipeptidyl peptidase 4 inhibitor 
(OR 0.51) or a glucagon-like peptide 1 agonist (OR 0.23) and significantly higher odds for 
patients receiving insulin (OR 2.77) or SU (OR 2.49) (22). When considering the prevalence of 
HG, the American Geriatrics Society recommends customizing glycemic control for older adults 
according to comorbidity, functional status, and life expectancy, noting that a target HbA1c of 
7.5% to 8% is often appropriate for older patients with multiple comorbidities or impaired 
functional status (23).
Risk factors for HG in DM (24-32) include basal and bolus insulin (33, 34), SU drugs (5, 
35, 36), chronic kidney disease (37), and certain combinations of medications for DM (38-40). 
Since clinicians should regularly assess the risk of HG in patients with DM (41, 42), an 
automated, point-of-care approach to estimating risk may help clinicians to save time and 
identify strategies to limit risk of HG among their patients. Based on a previously developed 
logistic regression model of HG, we created a computerized HG risk prediction tool that 
incorporates significant risk factors for HG [refer to companion article].
As adoption of electronic health record (EHR) systems increases (43), the need for EHR-
based clinical tools that can improve decision-making and outcomes is growing. The objective of 
this study was to implement a HG alert tool in an EHR system, and determine its effect on 
clinical practice and outcomes. The hypothesis was that the intervention group of PCPs using the 
tool would have greater frequencies of DM-medication changes and counseling of patients about 
HG.

































































To build a risk prediction model for HG, we first retrospectively studied risk factors 
identified in previously published articles and reports, to determine which were independently 
associated with HG in a local population. We targeted patients and outpatient primary care 
providers at Eskenazi Health on the campus of Indiana University-Purdue University 
Indianapolis. The retrospective study period was 2004 to 2013. Eligible patients were at least 21 
years of age on 01 January 2004 and were prescribed or dispensed a drug for DM during the 
study period. The index date was defined as the first HG event for a patient during the study 
period. For patients who did not experience a HG event, their index date was a randomly selected 
visit date during the study period. The baseline period was defined as the two years prior to the 
index date. We excluded patients with a diagnosis of abnormal glucose tolerance complicating 
pregnancy or childbirth, and patients with fewer than two clinical encounters on separate dates 
during the baseline period. From the Indiana Network for Patient Care (44, 45), we extracted 
data about risk factors and demographics, from medical records of patients seen at the institution 
during the study period. Using this retrospective cohort, we conducted multivariable logistic 
regression analysis, with HG as the primary outcome. HG was defined as an outpatient plasma 
glucose value of less than 70 mg/dL (3.9 mmol/L), identified through laboratory reports, 
International Classification of Diseases diagnosis codes (46), or narrative text (e.g., notes from 
clinical encounters) that underwent natural language processing (NLP) to identify episodes of 
HG. Significance was defined by a p-value of less than or equal to 0.05. In logistic regression, 
positive risk factors included the following: eating disorder, infection within 30 days, insulin 
other than long-acting insulin, previous HG within 12 months, African-American, diabetic 
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neuropathy, Medicaid, alcohol, chronic heart failure, no antibiotics, antibiotics with a SU drug, 
dementia or falls, and A1C 6.5% or less. Negative risk factors included serum calcium, long-
acting insulin plus a SU within 90 days, Hispanic, and age 75 or more years. The risk factors 
were then incorporated into a risk prediction tool that we designed and developed for clinicians. 
The tool was implemented over a four month period in 2016, for a random sample of outpatient 
primary care providers at Eskenazi Health. Outcomes were assessed during months five through 
nine, using an intention-to-treat analysis. The study was approved by the Institutional Review 
Board of Indiana University-Purdue University Indianapolis.
Setting and participants
The setting is Eskenazi Health, which is one of the five largest safety-net health 
institutions in the U.S. It is a tax-supported, urban healthcare system providing outpatient, 
inpatient, and community-based health services to residents of Marion County, Indiana. Sidney 
& Lois Eskenazi Hospital and a core of outpatient clinics are located on the campus of Indiana 
University-Purdue University Indianapolis. Additional community health centers providing 
primary care are located around the Indianapolis metropolitan area. In 2016, the institution 
reported 14,073 hospital admissions and 834,631 outpatient visits, including 236,945 visits to 
community health centers. The payer mix is 28% Medicaid, 20% Medicare, 11% commercial, 
and 24% uninsured. A special program of services is provided for many low-income patients 
who are not eligible for Medicaid benefits. Eskenazi Health has more than 1,000 physicians on 
its medical staff.
The Regenstrief G3 system is an advanced EHR system that includes computerized 
provider order entry (47). During the study period, G3 was Eskenazi's primary instrument for 































































includes clinical data representing over 90 hospitals, the public health departments, local 
laboratories, imaging centers, and selected large-group practices. Participating institutions share 
a common file structure and term dictionary. The Network includes information about laboratory 
tests, demographics, encounters, diagnosis codes, and some information about prescribing and 
pharmacy. The study included clinicians who were scheduled to provide primary care at 
Eskenazi Health during the four-month intervention period at the beginning of 2016.
Intervention
Working with technologists and software developers on our team, we developed and 
iteratively refined the risk prediction tool, which underwent user acceptance testing with a small 
group of test users. The tool was integrated into the EHR system. Based on a patient's 
characteristics, the tool was displayed at the edge of the computer display when a clinician 
logged into an eligible patient's electronic medical record. An example of the display is shown in 
Figure 1 (initial collapsed form) and Figure 2 (expanded). The tool displays the estimated two-
year risk of HG, along with an indication of the presence of risk factors identified in the patient's 
medical record. The user can test hypothetical clinical variants, by modifying variables directly 
within the tool, to update the display of HG risk. For example, the user could determine how 
much the HG risk would change if the patient's age or related diagnoses changed. A feedback 
feature was included so that users could send comments to the project team.
Outcomes
For patients in intervention and control groups, we reported demographics and risk 
factors for HG, which was the primary outcome. We reported clinical practice measures, 
including laboratory testing for glucose and A1C, changes to prescribing of medications for DM, 































































and patient education related to HG, as assessed by NLP. We also assessed the number of 
clinical encounters. We reported outcomes stratified by quintile of HG risk.
In reporting drugs, insulin was categorized as long-acting, short-acting, or pre-mixed. 
Prescriptions were categorized as new, changed, refilled (with no changes), or discontinued, 
according to the type of order generated for the prescription. A change to a prescription was 
defined as a prescription for a drug when the most recent prescription for the same drug had 
different instructions. A refill was defined as a prescription for a drug when the most recent 
prescription for the same drug had the same instructions. If the prescription were a refill or 
change, but the preceding instructions were not available, then the prescription was considered to 
be "unknown whether refilled or changed". We included prescriptions for glucagon (4) and 
glucose tablets (48).
Sample size
We anticipated that 100 providers (physicians and resident housestaff) would be available 
for provider-level randomization at equal chance to receive or not receive access to the HG alert 
tool, and that a provider would, on average, see 150 patients during the four-month intervention 
period. With a total of approximately 15,000 patients and, assuming that the intra-cluster 
(physician) correlation is 0.05, cluster size 150 (patients), a coefficient of variation of cluster size 
no more than 0.23, and a 10% HG rate for the group without the access to the HG alert tool 
during the follow-up period, we would have 80% power to detect, at a two-sided significance 
level of 0.05, an absolute difference of at least 3.8% in the incidence rates of HG between the 
study groups.
































































We randomized primary care clinicians who provide outpatient care at Eskenazi Health, 
to see, or not see, the alert tool in outpatient clinical practice, for four months. For clinicians in 
the intervention group, the tool was displayed for all outpatients who were 21 or more years of 
age and were prescribed any of the following drugs for DM: acarbose, acetohexamide, alogliptin, 
canagliflozin, chlorpropamide, colesevelam, dapagliflozin, exenatide, glibenclamide, 
glimepiride, glipizide, glyburide, insulin, linagliptin, liraglutide, meglitol, metformin, 
nateglinide, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, 
tolazamide, or voglibose. During the five-month follow-up period, we assessed patients' 
characteristics, prescriptions, diagnostic testing, and HG. Clinicians randomized to the control 
group did not see the computerized alert tool displayed for their patients while logged into the 
EHR.
Blinding
Clinicians in the intervention group did not receive specific training about the alert tool, 
because they are accustomed to seeing many different types of EHR-based alert tools without 
alert-specific training, and we sought to provide them with a typical experience in this regard, 
along with the availability of online documentation for those seeking details. Of course, the 
clinicians could not be blinded to the existence of the tool. Clinicians in the control group were 
not informed about the availability of the tool in the intervention group, but they might have 
learned about the tool through discussions with other healthcare personnel. The study team did 
not interact directly with the participating clinicians about the tool during the intervention period. 
The study design required the analyst to become aware of the group assignments during the 
analysis.
































































The index visit was defined as the first visit of an eligible patient to an outpatient primary 
care provider during the four-month intervention period. Intervention and control groups were 
analyzed with intention to treat, where the intervention was considered the treatment. Categorical 
variables with more than two levels were compared by a multinomial model, with fixed effect for 
the intervention group, and a random intercept for the primary care physician. Binary variables 
were compared by means of a logistic model, and continuous variables were compared by means 
of a linear model with similar independent variables. Similar methods were used to test for 
differences between quintiles of the predicted HG risk for intervention subjects. Analyses were 
conducted using SAS/STAT software, version 9.4 (SAS Institute, Inc., Cary, NC).
































































The intervention period was 14 January 2016 to 30 April 2016. The follow-up period was 
01 May 2016 to 30 September 2016. Table 1 shows the demographic and clinical characteristics 
of each group, as well as outcomes. Intervention (N=3350) and control (N=3395) patients visited 
220 PCPs. Patients' mean age was 55 years (SD 13), with 61% female, 49% black, 27% white, 
and 49% with Medicaid.
Outcomes by study group. Intervention PCPs (N=97) were shown 18,645 alerts about 
HG. Mean A1c (8.7%) and body mass index (35.2 kg/m2) were similar at baseline between 
groups (Table 1). During the five-month follow-up period, the frequency of A1c testing and HG 
events was unchanged. The intervention group had 172 subjects who had a total of 218 episodes 
of HG; the control group had 168 subjects who had a total of 219 episodes. Per 100 patients, the 
intervention group had significantly fewer SU refills (6 vs. 8; p<0.05) and fewer outpatient 
encounters (470 vs. 502; p<0.05). 
Outcomes by HG risk. We found numerous significant differences among quintiles of 
intervention patients by HG risk (Table 2). Patients with the highest risk of HG had more blood 
glucose tests, more A1c tests, and more new, refilled, changed, or discontinued insulin 
prescriptions. Although the mean A1c following the index date was about 8.5% at both extremes 
of HG risk, A1c before the index date was highest in the group with lowest HG risk.
Other measures. Few patients (N=13) had prescriptions for glucose tablets or glucagon, 
and few appeared to receive HG-specific education that was documented in the medical record. 
Clinicians' feedback about the alert tool indicated that the tool was useful, but the tool or its 
contents were not always prominent enough. Alert fatigue was mentioned as a potential barrier. 
In some cases, a greater understanding about the tool or its information was desired. 































































Anecdotally, we also noted that several clinicians commented that the risk numbers reported by 
the tool appeared "too high" for action; in other words, the numbers were sometimes difficult to 
believe. No harms were identified as a result of the intervention.
































































This study of 6,745 adult patients with diabetes who visited PCPs randomized to see or 
not see a HG alert tool showed that using the EHR to alert clinicians about the risk of HG was 
associated with 25% fewer SU refills and 6.4% fewer outpatient encounters over five months. 
These findings may be clinically and economically meaningful: the alert tool can have an impact 
in the management of DM. Because SU drugs have been associated with HG, "de-prescribing" or 
de-intensification of SU can be expected to help some patients with HG. In addition, fewer 
encounters may translate into cost savings. In the inpatient setting, clinical decision support has 
been shown to decrease the frequency of HG (49, 50), but the outpatient setting poses the 
additional challenges of more longitudinal care, less frequent contact with patients, and diversity 
of patients' settings.
Health information technologies are starting to prove useful in the management of DM. 
Mobile phones have been used (51, 52), including for dietary documentation (53). WellDocTM 
provided patients with mobile phone-based software with real-time feedback about glucose 
levels and medications, and sent electronic logs to the patients’ clinicians. This system led to a 
decrease in A1c (51). The use of secure messaging may help glycemic control, too (54). Virtual-
reality tools have been described (55, 56). Huang et al. reported that a Web-based decision-
support tool including an educational module, assessment of treatment preferences, personalized 
printout, and estimation of life expectancy and risk of complications was associated with 
decreased reports of HG over a one-month period (57). Tools based on robust analytics and 
requiring minimal training may be beneficial. Despite potential benefits, technologies require 
increased attention to the human factors involved in the interactions between person and 
machine. In Huang's study, which required training of patients and one hour of training of 































































clinicians, only 53% of physicians reported that their experience with the decision aid was 
acceptable. Our alert tool was clearly visible, but the feedback that we received indicated that the 
PCPs may not have always seen it. This phenomenon may have occurred due to the size or other 
aspects of the alert's design, or "competing" information on the screen. More comprehensive 
testing could be done to assess the alert's design-based characteristics and usability. Improving 
usability may directly increase users' responsiveness to alerts, thereby improving outcomes. 
Attending to usability among patients can also help. Wearable continuous glucose monitors can 
now alert patients about imminent HG, identify trends that inform important changes to self-
management, and decrease duration (58, 59) and incidence (60) of HG, but today's devices are 
still invasive and are out of many patients' price range (61).
The number of HG events was similar between study groups. Several factors may 
account for this. First, though we thought that five months would be enough time to see a 
response to a change in clinical practice, the follow-up period may still be too short. Second, the 
capture of HG events might be insufficient: we did not have access to home-based glucometers, 
so the study might preferentially identify only the most severe cases of HG. Third, the EHR-
based alert, though able to change clinical practice, might be insufficient to change the practices 
far beyond what PCPs are already doing; PCPs more frequently monitored glucose levels and 
changed insulin prescriptions in their high-risk patients. The alert tool may need to be coupled 
with greater education of both clinicians and patients regarding additional strategies to improve 
practice and self-management (62, 63). Our setting's high prevalence of low-income patients can 
pose a special challenge for self-management strategies, especially those that require resources 
such as glucometry supplies and adequate sources of nutrition. Timelier sharing of glucometry 
data between patients and their clinicians might help with adjustments to lifestyle or treatment 































































that could decrease risk of HG (64). As we found in this study, the alert tool could also benefit 
from greater visual prominence, which might lead to larger changes in practice.
PCPs sometimes underestimate the incidence of HG. In our study, several clinicians 
reported that the displayed HG risk appeared “too high to believe”. Many other studies have 
demonstrated the high incidence of HG in a variety of populations. In our population, we had 
verified the plausibility of our estimates: indeed, more than 5% of subjects had documented HG 
even during our short follow-up period. In addition, the expected risk of HG was correlated with 
the observed incidence. These results underscore our finding that the actual incidence of HG is 
often higher than clinicians appreciate or would guess, and suggests that clinicians could benefit 
from greater education about HG and how to work with their patients to improve safety. Cox et 
al. reported significant variation in physicians' knowledge about patients' symptoms and 
awareness of HG (65). In our study, although patients at the greatest risk of HG saw the most 
glucose and A1c testing, and the most changes to insulin prescriptions—and some degree of HG 
risk might not be readily modifiable—additional, more tailored changes to managing these 
patients appear warranted, including counseling and glucagon prescriptions. For some patients, 
tailored management might entail de-intensifying drug therapy, using  drugs associated with a 
lower risk of HG (66), or pursuing other strategies to narrow the range of blood glucose levels, to 
avoid both low and high extremes.
This study has limitations. Since the unit of randomization was the physician and not the 
patient, there could be imbalances in patient characteristics between groups. The use of both 
diagnosis codes and NLP to detect HG could be expected to detect most, but not all, of the HG 
events that came to the clinicians' attention. Mild to moderately severe cases may be under-
represented. Patient-identified and self-treated HG events are out of scope for this study. If the 































































text of a prescription's instructions changed, but the prescription's dose, route, and frequency did 
not actually change, the prescription would be classified as changed instead of refilled. Patients 
represented in this study come from an urban safety net and have a high prevalence of minorities, 
low income, and low education. Other types of patients might yield different outcomes. We have 
no reason to believe that the clinicians studied would treat DM and HG differently for different 
populations, or that other clinicians would treat HG in a significantly different way, but the study 
did not assess that.
In summary, displaying patients' risk of HG to PCPs led to 25% fewer SU refills and 
6.4% fewer outpatient encounters. Improving long-term incidence of HG and other outcomes 
may require greater attention to technical usability, more education of both PCPs and patients, 
and additional changes to clinical practice.
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21-44 664 (20) 791 (23) 0.3231
45-64 1954 (58) 1967 (58)
65-74 532 (16) 471 (14)
75-84 173 (5) 152 (4)
≥ 85 27 (1) 14 (0.4)
Gender
Female 2063 (62) 2060 (61) 0.4736
Male 1287 (38) 1335 (39)
Race
Black 1590 (47) 1685 (50) 0.0805
White 986 (29) 852 (25)
Spanish 163 (5) 180 (5)
Native American 8 (0.2) 4 (0.1)
Other 481 (14) 534 (16)
Unknown 122 (4) 140 (4)
Insurance
Medicaid within 90 days of index 
date 1569 (47) 1666 (49) 0.0599
Insured without Medicaid 1617 (48) 1656 (49)
Uninsured 164 (5) 73 (2)
Body mass index (kg/m2)
N 3323 3392
Mean ± SD 35.24 ± 9.19 35.18 ± 9.20 0.8703
Hypoglycemia
Within 12 months preceding study 
period: n subjects 448 (13) 436 (13) 0.9934
During study period 175 (5) 173 (5) 0.9921
Pre-existing medical conditions
Alcohol 290 (9) 310 (9) 0.4240
Autonomic failure 152 (4) 157 (5) 0.8635
Cancer 1479 (44) 1530 (45) 0.1633
Chronic heart failure 179 (5) 175 (5) 0.7343
Coronary artery disease 545 (16) 512 (15) 0.9148
Dementia 386 (12) 361 (11) 0.3822
Diabetic neuropathy 659 (20) 688 (20) 0.5054
Infection within 30 days of index 
date 201 (6) 214 (6) 0.5566
Last hospital discharge before index 
date, among those who were 
hospitalized
1-30 days before index date 117 (12) 183 (19) 0.3940
31-365 days 371 (39) 333 (35)
> 365 days 474 (49) 424 (45)








































































Last prior to index date
N 3181 3239
Mean ± SD 8.63 ±12.80 8.73 ±12.89 0.2478
≤ 6.5% 870 (27) 940 (29) 0.8143
> 6.5%, < 7% 364 (11) 323 (10)
≥ 7%, < 8% 644 (20) 650 (20)
≥ 8%, < 9% 423 (13) 409 (13)




Mean ± SD 8.28 ± 5.96 8.06 ± 3.55
Serum calcium (mg/dL) prior to 
index date
N 2969 2943
Mean ± SD 8.93 ± 0.51 8.91 ± 0.50 0.4115
Encounters before index date
Number of subjects with hospital 
admission in prior year 492 (15) 517 (15) 0.9963
Number of hospital admissions, 
mean per patient
Mean ± SD 0.30 ± 1.02 0.33 ± 1.20 0.8451
Number of outpatient encounters, 
total, in year prior
Mean ± SD 10.07 ± 8.39 10.37 ± 8.54 0.2666
Non-emergency outpatient, in year 
prior
Mean ± SD 9.29 ± 7.83 9.54 ± 7.80 0.3262
Emergency department, in year prior
Mean ± SD 0.78 ± 1.60 0.83 ± 1.62 0.2442
Encounters in 5 months after index
Number of subjects with hospital 
admission 230 (7) 231 (7) 0.8765
Number of hospital admissions, 
mean per patient
Mean ± SD 0.10 ± 0.50 0.10 ± 0.57 0.4566
Number of outpatient encounters, 
total
Mean ± SD 4.70 ± 4.54 5.02 ± 4.48 0.0178
Non-emergency outpatient
Mean ± SD 4.39 ± 4.26 4.68 ± 4.18 0.0247
Emergency department
Mean ± SD 0.31 ± 0.78 0.34 ± 0.85 0.2000
Any insulin in 5 months after index 
date, N (%) 537 (16) 482 (14) 0.2118
Long-acting insulin in 5 months 
after index date







































































Subjects with at least 1 
Prescription
N (%) 303 (9) 265 (8) 0.3755
Number of Prescriptions
Mean ± SD 2.20 ± 1.84 2.44 ± 2.91
New
Mean ± SD 0.04 ± 0.27 0.04 ± 0.28 0.8856
Refilled
Mean ± SD 0.03 ± 0.21 0.02 ± 0.20 0.4993
Changed
Mean ± SD 0.04 ± 0.30 0.05 ± 0.51 0.2540
Discontinued
Mean ± SD 0.03 ± 0.20 0.03 ± 0.20 0.7792
Unknown whether refilled or 
changed
Mean ± SD 0.06 ± 0.23 0.04 ± 0.21 0.1276
Short-acting insulin in 5 months 
after index date
Subjects with at least 1 
Prescription
N (%) 169 (5) 183 (5) 0.4656
Number of Prescriptions
Mean ± SD 1.72 ± 1.00 1.76 ± 1.57
New
Mean ± SD 0.03 ± 0.18 0.03 ± 0.20 0.5934
Refilled
Mean ± SD 0.01 ± 0.11 0.01 ± 0.13 0.3056
Changed
Mean ± SD 0.01 ± 0.15 0.01 ± 0.20 0.9087
Discontinued
Mean ± SD 0.02 ± 0.12 0.02 ± 0.14 0.2753
Unknown whether refilled or 
changed
Mean ± SD 0.02 ± 0.16 0.02 ± 0.15 0.6598
Pre-mixed insulin(e.g., 70/30 or 
75/25) in 5 months after index date
Subjects with at least 1 
Prescription
N (%) 149 (4) 115 (3) 0.1015
Number of Prescriptions
Mean ± SD 2.00 ± 1.72 2.04 ± 1.58
New
Mean ± SD 0.01 ± 0.14 0.01 ± 0.12 0.5492
Refilled
Mean ± SD 0.01 ± 0.17 0.01 ± 0.16 0.6967
Changed
Mean ± SD 0.02 ± 0.17 0.01 ± 0.14 0.2611
Discontinued
Mean ± SD 0.01 ± 0.12 0.01 ± 0.12 0.7599







































































Unknown whether refilled or 
changed
Mean ± SD 0.04 ± 0.19 0.02 ± 0.15 0.0294
Sulfonylurea in 5 months after index 
date
N Subjects with at least 1 
Prescription (%) 724 (22) 827 (24) 0.0931
Number of Prescriptions
Mean ± SD 1.50 ± 0.88 1.55 ± 0.84 0.2286
New
Mean ± SD 0.06 ± 0.27 0.07 ± 0.26 0.0584
Refilled
Mean ± SD 0.06 ± 0.27 0.08 ± 0.33 0.0143
Changed
Mean ± SD 0.02 ± 0.16 0.02 ± 0.18 0.2788
Discontinued
Mean ± SD 0.04 ± 0.22 0.05 ± 0.22 0.6878
Unknown whether refilled or 
changed
Mean ± SD 0.15 ± 0.36 0.16 ± 0.37 0.2991




Unknown whether refilled or 
changed 1 1





Unknown whether refilled or 
changed 1 1
Antibiotics in 5 months after index 
date
Number of Subjects with at least 1 
Prescription
Mean ± SD 0.20 ± 0.40 0.19 ± 0.39 0.5669
Number of Prescriptions
Mean ± SD 0.39 ± 1.12 0.37 ± 1.01 0.6572
New
Mean ± SD 0.17 ± 0.54 0.15 ± 0.48 0.3345
Refilled
Mean ± SD 0.03 ± 0.24 0.03 ± 0.20 0.6583
Changed
Mean ± SD 0.01 ± 0.14 0.02 ± 0.17 0.1464
Discontinued
Mean ± SD 0.15 ± 0.45 0.15 ± 0.45 0.9649







































































Unknown whether refilled or 
changed
Mean ± SD 0.03 ± 0.17 0.02 ± 0.14 0.3832
Number of diagnostic tests in 5 
months after index date
A1C
Mean ± SD 0.72 ± 0.72 0.74 ± 0.72 0.0728
Glucose level
Mean ± SD 1.55 ± 3.57 1.63 ± 3.91 0.4920
Creatinine
Mean ± SD 1.20 ± 3.08 1.22 ± 3.20 0.6280
Glomerular filtration rate, estimated 
(mL/min/1.73m2), baseline period
N 2888 2853
Mean ± SD 103.16 ±40.07 104.39 ±38.47 0.8177
Patient education related to 
hypoglycemia 2 8 





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
HG Risk Score
N 670 670 670 670 670
Mean ± SD 0.14 ± 0.05 0.26 ± 0.03 0.36 ± 0.03 0.48 ± 0.04 0.72 ± 0.11 <.0001










Subjects (%) with HG
In 12 months preceding 
study period
50 (8) 50 (8) 72 (11) 85 (13) 191 (29) <.0001
During study period 23 (3) 19 (3) 31 (5) 32 (5) 70 (10) <.0001
Age
Mean ± SD 50.1 ±12.8 53.6 ±12.3 55.1 ±12.7 57.6 ±12.7 59.2 ±11.5 <.0001
Median (Min, Max) 51 (21, 92) 54 (22, 90) 56 (21, 89) 58.5 (21, 90) 60 (24, 90)
Gender <.0001
Female 380 (57) 415 (62) 450 (67) 385 (57) 433 (65)
Male 290 (43) 255 (38) 220 (33) 285 (42) 237 (35)
Race <.0001
White 196 (29) 229 (34) 212 (32) 183 (27) 166 (25)
Black 146 (22) 227 (34) 335 (50) 408 (6) 474 (71)
Hispanic 85 (13) 38 (6) 21 (3) 16 (2) 3 (0.4)
Native American 2 (0.3) 4 (1) 1 (0.1) 1 (0.1) 0 (0.0)
Other 199 (30) 134 (20) 81 (12) 48 (7) 19 (3)




362 (54) 370 (55) 337 (50) 281 (42) 219 (33) <.0001
Medicaid 261 (39) 269 (40) 288 (43) 368 (55) 431 (64)































































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Uninsured 47 (7) 31 (5) 45 (7) 21 (3) 20 (3)
Body Mass Index (kg/m2)
N 663 666 663 664 667
Mean ± SD 35.87 ± 9.83 36.00 ± 9.22 35.75 ± 9.25 34.16 ± 8.30 34.43 ± 9.13 <.0001
Median (Min, Max) 34 (14, 80) 35 (15, 82) 34 (14, 78) 33 (12, 89) 33 (12, 71)
Prior medical conditions
Alcohol 32 (5) 43 (6) 51 (8) 71 (11) 93 (14) <.0001
Autonomic failure 43 (6) 22 (3) 18 (3) 30 (4) 39 (6) 0.0032
Cancer 229 (34) 252 (38) 299 (45) 313 (47) 386 (58) <.0001
Chronic heart failure 8 (1) 8 (1) 14 (2) 43 (6) 106 (16) <.0001
Coronary artery disease 51 (8) 60 (9) 77 (12) 141 (21) 216 (32) <.0001
Dementia 36 (5) 52 (8) 78 (12) 87 (13) 133 (20) <.0001
Diabetic neuropathy 107 (16) 86 (13) 82 (12) 149 (22) 235 (35) <.0001
Infection within 30 days 
of index date
32 (5) 37 (6) 39 (6) 40 (6) 53 (8) 0.1692
Last hospital discharge 
before index date
N 565 570 514 435 304
1-30 days 10 (9) 4 (4) 8 (5) 29 (12) 66 (18) <.0001
31-365 days 31 (30) 41 (41) 56 (36) 81 (34) 162 (44)
> 365 days 64 (61) 55 (55) 92 (59) 125 (53) 138 (38)
Last A1C prior to index 
date
N 599 643 639 645 655
Mean ± SD 10.01 ±23.73 8.68 ±10.58 8.12 ± 4.18 8.35 ±12.23 8.09 ± 2.23 0.0145
Missing 71 27 31 25 15 
≤ 6.5% 123 (21) 170 (26) 191 (30) 204 (32) 182 (28) <.0001































































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
> 6.5% to < 7% 59 (10) 86 (13) 76 (12) 72 (11) 71 (11)
≥ 7% to < 8% 133 (22) 119 (19) 131 (20) 124 (19) 137 (21)
≥ 8% to < 9% 84 (14) 92 (14) 81 (13) 91 (14) 75 (11)
≤ 9% 200 (33) 176 (27) 160 (25) 154 (24) 190 (29)
A1C after index date
N 375 363 372 404 432
Mean ± SD 8.50 ± 8.01 8.52 ± 6.44 7.79 ± 1.90 8.00 ± 2.09 8.54 ± 7.89
A1C change
N 349 356 360 396 426
Mean ± SD -2.53 ± 31.72 -0.70 ± 15.26 -0.18 ± 1.58 -0.74 ± 15.15 0.44 ± 7.97 0.1860
Number of subjects with 
any insulin in 5 months 
after index date
78 (12) 84 (13) 88 (13) 114 (17) 173 (26) <.0001
Long-acting insulin 
prescriptions in 5 months 
after index date
Number of Subjects with at 
least one Prescription (%)
48 (7) 45 (7) 44 (7) 64 (10) 102 (15) <.0001
Number of Prescriptions
Mean ± SD 2.29 ± 2.00 1.96 ± 1.46 2.00 ± 1.35 2.16 ± 1.83 2.37 ± 2.09 <.0001
Median (Min, Max) 2 (1, 12) 1 (1, 7) 2 (1, 8) 2 (1, 11) 2 (1, 12)
New
Mean ± SD 0.04 ± 0.23 0.02 ± 0.17 0.03 ± 0.20 0.04 ± 0.25 0.10 ± 0.43 <.0001
Median (Min, Max) 0 (0, 2) 0 (0, 2) 0 (0, 2) 0 (0, 3) 0 (0, 5)
Refilled
Mean ± SD 0.03 ± 0.23 0.02 ± 0.21 0.02 ± 0.21 0.03 ± 0.23 0.03 ± 0.18 0.8658































































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Changed
Mean ± SD 0.03 ± 0.28 0.02 ± 0.23 0.02 ± 0.18 0.04 ± 0.30 0.08 ± 0.43 0.0008
Discontinued
Mean ± SD 0.03 ± 0.21 0.01 ± 0.13 0.02 ± 0.13 0.03 ± 0.21 0.05 ± 0.28 0.0026
Short-acting insulin 
prescriptions in 5 months 
after index date
N subjects with at least one 
prescription (%)
20 (3.0) 28 (4.2) 32 (4.8) 32 (4.8) 57 (8.5) 0.0001
Number of Prescriptions
Mean ± SD 2.05 ± 1.15 1.64 ± 0.99 1.62 ± 1.01 1.62 ± 0.94 1.74 ± 0.96
New
Mean ± SD 0.02 ± 0.15 0.02 ± 0.18 0.02 ± 0.13 0.02 ± 0.15 0.05 ± 0.25 0.0090
Refilled
Mean ± SD 0.004 ± 0.086 0.004 ± 0.067 0.01 ± 0.10 0.01 ± 0.13 0.02 ± 0.15 0.4168
Changed
Mean ± SD 0.02 ± 0.16 0.01 ± 0.14 0.02 ± 0.19 0.01 ± 0.11 0.02 ± 0.13 0.6999
Discontinued
Mean ± SD 0.01 ± 0.10 0.01 ± 0.13 0.01 ± 0.09 0.01 ± 0.09 0.03 ± 0.18 0.0010
Pre-mixed insulin 
prescriptions in 5 months 
after index date
N subjects with at least one 
prescription (%)
22 (3) 24 (4) 24 (4) 31 (5) 48 (7) 0.0032
Number of Prescriptions
Mean ± SD 1.86 ± 1.32 1.29 ± 0.55 2.08 ± 1.72 1.71 ± 1.13 2.56 ± 2.33
Median (Min, Max) 1 (1, 6) 1 (1, 3) 1 (1, 7) 1 (1, 6) 2 (1, 12)
New
Mean ± SD 0.003 ± 0.055 0.004 ± 0.067 0.02 ± 0.15 0.01 ± 0.10 0.03 ± 0.24 0.0137































































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Refilled
Mean ± SD 0.004 ± 0.086 0.01 ± 0.10 0.01 ± 0.09 0.02 ± 0.18 0.04 ± 0.29 0.0034
Changed
Mean ± SD 0.02 ± 0.17 0.001 ± 0.039 0.01 ± 0.10 0.01 ± 0.14 0.03 ± 0.29 0.0098
Discontinued
Mean ± SD 0.01 ± 0.12 0.01 ± 0.08 0.01 ± 0.13 0.01 ± 0.08 0.03 ± 0.18 0.0066
Sulfonylurea prescriptions 
in 5 months after index 
date
N subjects with at least one 
prescription (%)
167 (25) 148 (22) 158 (24) 144 (21) 107 (16) 0.0003 
Number of Prescriptions
Mean ± SD 1.44 ± 0.69 1.49 ± 0.82 1.38 ± 0.82 1.62 ± 1.04 1.60 ± 1.01
New
Mean ± SD 0.07 ± 0.26 0.06 ± 0.27 0.05 ± 0.24 0.05 ± 0.30 0.05 ± 0.26 0.5691
Refilled
Mean ± SD 0.07 ± 0.29 0.05 ± 0.24 0.04 ± 0.22 0.07 ± 0.32 0.05 ± 0.28 0.1355
Changed
Mean ± SD 0.02 ± 0.13 0.03 ± 0.20 0.02 ± 0.20 0.02 ± 0.17 0.004 ± 0.086 0.1123
Discontinued
Mean ± SD 0.05 ± 0.23 0.04 ± 0.22 0.04 ± 0.22 0.05 ± 0.23 0.04 ± 0.20 0.8869
A1c tests in 5 months after 
index date
Subjects with at least 1 
test
N 375 363 372 404 432































































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Mean ± SD 1.20 ± 0.48 1.20 ± 0.45 1.20 ± 0.44 1.22 ± 0.46 1.35 ± 0.63
All subjects
N 670 670 670 670 670
Mean ± SD 0.67 ± 0.70 0.65 ± 0.68 0.67 ± 0.68 0.73 ± 0.70 0.87 ± 0.82 <.0001






























































Figure 1. Alert tool in initial collapsed form. The alert shows the two-year risk of hypoglycemia. 
It provides a link ("Learn more and see options") to expand the display to show more 
information (see Figure 2).
Figure 2. Alert tool in expanded form. Patients' characteristics that contribute to risk of 
hypoglycemia are shown. The user can modify these to test hypothetical scenarios.
































































Figure 1. Alert tool in initial collapsed form.
Figure 2. Alert tool in expanded form.






































































21-44 664 (20) 791 (23) 0.3231
45-64 1954 (58) 1967 (58)
65-74 532 (16) 471 (14)
75-84 173 (5) 152 (4)
≥ 85 27 (1) 14 (0.4)
Gender
Female 2063 (62) 2060 (61) 0.4736
Male 1287 (38) 1335 (39)
Race
Black 1590 (47) 1685 (50) 0.0805
White 986 (29) 852 (25)
Spanish 163 (5) 180 (5)
Native American 8 (0.2) 4 (0.1)
Other 481 (14) 534 (16)
Unknown 122 (4) 140 (4)
Insurance
Medicaid within 90 days of index 
date 1569 (47) 1666 (49) 0.0599
Insured without Medicaid 1617 (48) 1656 (49)
Uninsured 164 (5) 73 (2)
Body mass index (kg/m2)
N 3323 3392
Mean ± SD 35.24 ± 9.19 35.18 ± 9.20 0.8703
Hypoglycemia
Within 12 months preceding study 
period: n subjects 448 (13) 436 (13) 0.9934
During study period 175 (5) 173 (5) 0.9921
Pre-existing medical conditions
Alcohol 290 (9) 310 (9) 0.4240
Autonomic failure 152 (4) 157 (5) 0.8635
Cancer 1479 (44) 1530 (45) 0.1633
Chronic heart failure 179 (5) 175 (5) 0.7343
Coronary artery disease 545 (16) 512 (15) 0.9148
Dementia 386 (12) 361 (11) 0.3822
Diabetic neuropathy 659 (20) 688 (20) 0.5054
Infection within 30 days of index 
date 201 (6) 214 (6) 0.5566
Last hospital discharge before index 
date, among those who were 
hospitalized
1-30 days before index date 117 (12) 183 (19) 0.3940
31-365 days 371 (39) 333 (35)
> 365 days 474 (49) 424 (45)
A1c
Last prior to index date
N 3181 3239
Mean ± SD 8.63 ±12.80 8.73 ±12.89 0.2478





































































≤ 6.5% 870 (27) 940 (29) 0.8143
> 6.5%, < 7% 364 (11) 323 (10)
≥ 7%, < 8% 644 (20) 650 (20)
≥ 8%, < 9% 423 (13) 409 (13)




Mean ± SD 8.28 ± 5.96 8.06 ± 3.55
Serum calcium (mg/dL) prior to 
index date
N 2969 2943
Mean ± SD 8.93 ± 0.51 8.91 ± 0.50 0.4115
Encounters before index date
Number of subjects with hospital 
admission in prior year 492 (15) 517 (15) 0.9963
Number of hospital admissions, 
mean per patient
Mean ± SD 0.30 ± 1.02 0.33 ± 1.20 0.8451
Number of outpatient encounters, 
total, in year prior
Mean ± SD 10.07 ± 8.39 10.37 ± 8.54 0.2666
Non-emergency outpatient, in year 
prior
Mean ± SD 9.29 ± 7.83 9.54 ± 7.80 0.3262
Emergency department, in year prior
Mean ± SD 0.78 ± 1.60 0.83 ± 1.62 0.2442
Encounters in 5 months after index
Number of subjects with hospital 
admission 230 (7) 231 (7) 0.8765
Number of hospital admissions, 
mean per patient
Mean ± SD 0.10 ± 0.50 0.10 ± 0.57 0.4566
Number of outpatient encounters, 
total
Mean ± SD 4.70 ± 4.54 5.02 ± 4.48 0.0178
Non-emergency outpatient
Mean ± SD 4.39 ± 4.26 4.68 ± 4.18 0.0247
Emergency department
Mean ± SD 0.31 ± 0.78 0.34 ± 0.85 0.2000
Any insulin in 5 months after index 
date, N (%) 537 (16) 482 (14) 0.2118
Long-acting insulin in 5 months 
after index date
Subjects with at least 1 
Prescription
N (%) 303 (9) 265 (8) 0.3755
Number of Prescriptions
Mean ± SD 2.20 ± 1.84 2.44 ± 2.91






































































Mean ± SD 0.04 ± 0.27 0.04 ± 0.28 0.8856
Refilled
Mean ± SD 0.03 ± 0.21 0.02 ± 0.20 0.4993
Changed
Mean ± SD 0.04 ± 0.30 0.05 ± 0.51 0.2540
Discontinued
Mean ± SD 0.03 ± 0.20 0.03 ± 0.20 0.7792
Unknown whether refilled or 
changed
Mean ± SD 0.06 ± 0.23 0.04 ± 0.21 0.1276
Short-acting insulin in 5 months 
after index date
Subjects with at least 1 
Prescription
N (%) 169 (5) 183 (5) 0.4656
Number of Prescriptions
Mean ± SD 1.72 ± 1.00 1.76 ± 1.57
New
Mean ± SD 0.03 ± 0.18 0.03 ± 0.20 0.5934
Refilled
Mean ± SD 0.01 ± 0.11 0.01 ± 0.13 0.3056
Changed
Mean ± SD 0.01 ± 0.15 0.01 ± 0.20 0.9087
Discontinued
Mean ± SD 0.02 ± 0.12 0.02 ± 0.14 0.2753
Unknown whether refilled or 
changed
Mean ± SD 0.02 ± 0.16 0.02 ± 0.15 0.6598
Pre-mixed insulin(e.g., 70/30 or 
75/25) in 5 months after index date
Subjects with at least 1 
Prescription
N (%) 149 (4) 115 (3) 0.1015
Number of Prescriptions
Mean ± SD 2.00 ± 1.72 2.04 ± 1.58
New
Mean ± SD 0.01 ± 0.14 0.01 ± 0.12 0.5492
Refilled
Mean ± SD 0.01 ± 0.17 0.01 ± 0.16 0.6967
Changed
Mean ± SD 0.02 ± 0.17 0.01 ± 0.14 0.2611
Discontinued
Mean ± SD 0.01 ± 0.12 0.01 ± 0.12 0.7599
Unknown whether refilled or 
changed
Mean ± SD 0.04 ± 0.19 0.02 ± 0.15 0.0294
Sulfonylurea in 5 months after index 
date





































































N Subjects with at least 1 
Prescription (%) 724 (22) 827 (24) 0.0931
Number of Prescriptions
Mean ± SD 1.50 ± 0.88 1.55 ± 0.84 0.2286
New
Mean ± SD 0.06 ± 0.27 0.07 ± 0.26 0.0584
Refilled
Mean ± SD 0.06 ± 0.27 0.08 ± 0.33 0.0143
Changed
Mean ± SD 0.02 ± 0.16 0.02 ± 0.18 0.2788
Discontinued
Mean ± SD 0.04 ± 0.22 0.05 ± 0.22 0.6878
Unknown whether refilled or 
changed
Mean ± SD 0.15 ± 0.36 0.16 ± 0.37 0.2991




Unknown whether refilled or 
changed 1 1





Unknown whether refilled or 
changed 1 1
Antibiotics in 5 months after index 
date
Number of Subjects with at least 1 
Prescription
Mean ± SD 0.20 ± 0.40 0.19 ± 0.39 0.5669
Number of Prescriptions
Mean ± SD 0.39 ± 1.12 0.37 ± 1.01 0.6572
New
Mean ± SD 0.17 ± 0.54 0.15 ± 0.48 0.3345
Refilled
Mean ± SD 0.03 ± 0.24 0.03 ± 0.20 0.6583
Changed
Mean ± SD 0.01 ± 0.14 0.02 ± 0.17 0.1464
Discontinued
Mean ± SD 0.15 ± 0.45 0.15 ± 0.45 0.9649
Unknown whether refilled or 
changed
Mean ± SD 0.03 ± 0.17 0.02 ± 0.14 0.3832
Number of diagnostic tests in 5 
months after index date
A1C





































































Mean ± SD 0.72 ± 0.72 0.74 ± 0.72 0.0728
Glucose level
Mean ± SD 1.55 ± 3.57 1.63 ± 3.91 0.4920
Creatinine
Mean ± SD 1.20 ± 3.08 1.22 ± 3.20 0.6280
Glomerular filtration rate, estimated 
(mL/min/1.73m2), baseline period
N 2888 2853
Mean ± SD 103.16 ±40.07 104.39 ±38.47 0.8177
Patient education related to 
hypoglycemia 2 8 





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
HG Risk Score
N 670 670 670 670 670
Mean ± SD 0.14 ± 0.05 0.26 ± 0.03 0.36 ± 0.03 0.48 ± 0.04 0.72 ± 0.11 <.0001










Subjects (%) with HG
In 12 months preceding 
study period
50 (8) 50 (8) 72 (11) 85 (13) 191 (29) <.0001
During study period 23 (3) 19 (3) 31 (5) 32 (5) 70 (10) <.0001
Age
Mean ± SD 50.1 ±12.8 53.6 ±12.3 55.1 ±12.7 57.6 ±12.7 59.2 ±11.5 <.0001
Median (Min, Max) 51 (21, 92) 54 (22, 90) 56 (21, 89) 58.5 (21, 90) 60 (24, 90)
Gender <.0001
Female 380 (57) 415 (62) 450 (67) 385 (57) 433 (65)
Male 290 (43) 255 (38) 220 (33) 285 (42) 237 (35)
Race <.0001
White 196 (29) 229 (34) 212 (32) 183 (27) 166 (25)
Black 146 (22) 227 (34) 335 (50) 408 (6) 474 (71)
Hispanic 85 (13) 38 (6) 21 (3) 16 (2) 3 (0.4)
Native American 2 (0.3) 4 (1) 1 (0.1) 1 (0.1) 0 (0.0)
Other 199 (30) 134 (20) 81 (12) 48 (7) 19 (3)




362 (54) 370 (55) 337 (50) 281 (42) 219 (33) <.0001
Medicaid 261 (39) 269 (40) 288 (43) 368 (55) 431 (64)
Uninsured 47 (7) 31 (5) 45 (7) 21 (3) 20 (3)





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Body Mass Index (kg/m2)
N 663 666 663 664 667
Mean ± SD 35.87 ± 9.83 36.00 ± 9.22 35.75 ± 9.25 34.16 ± 8.30 34.43 ± 9.13 <.0001
Median (Min, Max) 34 (14, 80) 35 (15, 82) 34 (14, 78) 33 (12, 89) 33 (12, 71)
Prior medical conditions
Alcohol 32 (5) 43 (6) 51 (8) 71 (11) 93 (14) <.0001
Autonomic failure 43 (6) 22 (3) 18 (3) 30 (4) 39 (6) 0.0032
Cancer 229 (34) 252 (38) 299 (45) 313 (47) 386 (58) <.0001
Chronic heart failure 8 (1) 8 (1) 14 (2) 43 (6) 106 (16) <.0001
Coronary artery disease 51 (8) 60 (9) 77 (12) 141 (21) 216 (32) <.0001
Dementia 36 (5) 52 (8) 78 (12) 87 (13) 133 (20) <.0001
Diabetic neuropathy 107 (16) 86 (13) 82 (12) 149 (22) 235 (35) <.0001
Infection within 30 days 
of index date
32 (5) 37 (6) 39 (6) 40 (6) 53 (8) 0.1692
Last hospital discharge 
before index date
N 565 570 514 435 304
1-30 days 10 (9) 4 (4) 8 (5) 29 (12) 66 (18) <.0001
31-365 days 31 (30) 41 (41) 56 (36) 81 (34) 162 (44)
> 365 days 64 (61) 55 (55) 92 (59) 125 (53) 138 (38)
Last A1C prior to index 
date
N 599 643 639 645 655
Mean ± SD 10.01 ±23.73 8.68 ±10.58 8.12 ± 4.18 8.35 ±12.23 8.09 ± 2.23 0.0145
Missing 71 27 31 25 15 
≤ 6.5% 123 (21) 170 (26) 191 (30) 204 (32) 182 (28) <.0001
> 6.5% to < 7% 59 (10) 86 (13) 76 (12) 72 (11) 71 (11)





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
≥ 7% to < 8% 133 (22) 119 (19) 131 (20) 124 (19) 137 (21)
≥ 8% to < 9% 84 (14) 92 (14) 81 (13) 91 (14) 75 (11)
≤ 9% 200 (33) 176 (27) 160 (25) 154 (24) 190 (29)
A1C after index date
N 375 363 372 404 432
Mean ± SD 8.50 ± 8.01 8.52 ± 6.44 7.79 ± 1.90 8.00 ± 2.09 8.54 ± 7.89
A1C change
N 349 356 360 396 426
Mean ± SD -2.53 ± 31.72 -0.70 ± 15.26 -0.18 ± 1.58 -0.74 ± 15.15 0.44 ± 7.97 0.1860
Number of subjects with 
any insulin in 5 months 
after index date
78 (12) 84 (13) 88 (13) 114 (17) 173 (26) <.0001
Long-acting insulin 
prescriptions in 5 months 
after index date
Number of Subjects with at 
least one Prescription (%)
48 (7) 45 (7) 44 (7) 64 (10) 102 (15) <.0001
Number of Prescriptions
Mean ± SD 2.29 ± 2.00 1.96 ± 1.46 2.00 ± 1.35 2.16 ± 1.83 2.37 ± 2.09 <.0001
Median (Min, Max) 2 (1, 12) 1 (1, 7) 2 (1, 8) 2 (1, 11) 2 (1, 12)
New
Mean ± SD 0.04 ± 0.23 0.02 ± 0.17 0.03 ± 0.20 0.04 ± 0.25 0.10 ± 0.43 <.0001
Median (Min, Max) 0 (0, 2) 0 (0, 2) 0 (0, 2) 0 (0, 3) 0 (0, 5)
Refilled
Mean ± SD 0.03 ± 0.23 0.02 ± 0.21 0.02 ± 0.21 0.03 ± 0.23 0.03 ± 0.18 0.8658





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Changed
Mean ± SD 0.03 ± 0.28 0.02 ± 0.23 0.02 ± 0.18 0.04 ± 0.30 0.08 ± 0.43 0.0008
Discontinued
Mean ± SD 0.03 ± 0.21 0.01 ± 0.13 0.02 ± 0.13 0.03 ± 0.21 0.05 ± 0.28 0.0026
Short-acting insulin 
prescriptions in 5 months 
after index date
N subjects with at least one 
prescription (%)
20 (3.0) 28 (4.2) 32 (4.8) 32 (4.8) 57 (8.5) 0.0001
Number of Prescriptions
Mean ± SD 2.05 ± 1.15 1.64 ± 0.99 1.62 ± 1.01 1.62 ± 0.94 1.74 ± 0.96
New
Mean ± SD 0.02 ± 0.15 0.02 ± 0.18 0.02 ± 0.13 0.02 ± 0.15 0.05 ± 0.25 0.0090
Refilled
Mean ± SD 0.004 ± 0.086 0.004 ± 0.067 0.01 ± 0.10 0.01 ± 0.13 0.02 ± 0.15 0.4168
Changed
Mean ± SD 0.02 ± 0.16 0.01 ± 0.14 0.02 ± 0.19 0.01 ± 0.11 0.02 ± 0.13 0.6999
Discontinued
Mean ± SD 0.01 ± 0.10 0.01 ± 0.13 0.01 ± 0.09 0.01 ± 0.09 0.03 ± 0.18 0.0010
Pre-mixed insulin 
prescriptions in 5 months 
after index date
N subjects with at least one 
prescription (%)
22 (3) 24 (4) 24 (4) 31 (5) 48 (7) 0.0032
Number of Prescriptions
Mean ± SD 1.86 ± 1.32 1.29 ± 0.55 2.08 ± 1.72 1.71 ± 1.13 2.56 ± 2.33
Median (Min, Max) 1 (1, 6) 1 (1, 3) 1 (1, 7) 1 (1, 6) 2 (1, 12)
New
Mean ± SD 0.003 ± 0.055 0.004 ± 0.067 0.02 ± 0.15 0.01 ± 0.10 0.03 ± 0.24 0.0137





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Refilled
Mean ± SD 0.004 ± 0.086 0.01 ± 0.10 0.01 ± 0.09 0.02 ± 0.18 0.04 ± 0.29 0.0034
Changed
Mean ± SD 0.02 ± 0.17 0.001 ± 0.039 0.01 ± 0.10 0.01 ± 0.14 0.03 ± 0.29 0.0098
Discontinued
Mean ± SD 0.01 ± 0.12 0.01 ± 0.08 0.01 ± 0.13 0.01 ± 0.08 0.03 ± 0.18 0.0066
Sulfonylurea prescriptions 
in 5 months after index 
date
N subjects with at least one 
prescription (%)
167 (25) 148 (22) 158 (24) 144 (21) 107 (16) 0.0003 
Number of Prescriptions
Mean ± SD 1.44 ± 0.69 1.49 ± 0.82 1.38 ± 0.82 1.62 ± 1.04 1.60 ± 1.01
New
Mean ± SD 0.07 ± 0.26 0.06 ± 0.27 0.05 ± 0.24 0.05 ± 0.30 0.05 ± 0.26 0.5691
Refilled
Mean ± SD 0.07 ± 0.29 0.05 ± 0.24 0.04 ± 0.22 0.07 ± 0.32 0.05 ± 0.28 0.1355
Changed
Mean ± SD 0.02 ± 0.13 0.03 ± 0.20 0.02 ± 0.20 0.02 ± 0.17 0.004 ± 0.086 0.1123
Discontinued
Mean ± SD 0.05 ± 0.23 0.04 ± 0.22 0.04 ± 0.22 0.05 ± 0.23 0.04 ± 0.20 0.8869
A1c tests in 5 months after 
index date
Subjects with at least 1 
test
N 375 363 372 404 432





























































Table 2. Characteristics of intervention patients, by quintile of estimated risk of hypoglycemia (HG)
HG Risk Quintile
Characteristic 1 2 3 4 5 p-value
Mean ± SD 1.20 ± 0.48 1.20 ± 0.45 1.20 ± 0.44 1.22 ± 0.46 1.35 ± 0.63
All subjects
N 670 670 670 670 670
Mean ± SD 0.67 ± 0.70 0.65 ± 0.68 0.67 ± 0.68 0.73 ± 0.70 0.87 ± 0.82 <.0001





























































Figure 1. Alert tool in initial collapsed form. The alert shows the two-year risk of hypoglycemia. It provides a 
link ("Learn more and see options") to expand the display to show more information (see Figure 2). 
228x143mm (120 x 120 DPI) 





























































Figure 2. Alert tool in expanded form. Patients' characteristics that contribute to risk of hypoglycemia are 
shown. The user can modify these to test hypothetical scenarios. 
129x175mm (120 x 120 DPI) 
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